Related posts

Danish software engineer and Microsoft technical fellow, creator of Turbo Pascal and Delphi and lead architect of C# and TypeScript.

• Our readingkorrents.com

  You cannot be best of breed in an ecosystem by telling its developers to write in a different programming language.

  JavaScript

  Their words

  I mean, surely you're not going to be best of breed in the JavaScript ecosystem by telling people to write in a different programming language.

  youtube.com

Co-creator of Django and creator of Datasette; writes daily at simonwillison.net.

• Lovedrcmnd.app

  Starlette

  Their words

  Kim Christie started working on Starlette in 2018 and it quickly became my favorite out of the new breed of Python ASGI frameworks.

  simonwillison.net

Researcher and science writer. Co-founder and editor at Works in Progress magazine, formerly a researcher at Our World in Data, and author of the Scientific Discovery newsletter on science, global health and medical innovation.

• Lovedrcmnd.app

  Genentech: The Beginnings of Biotech

  Their words

  This amazing book traces the development of genetic engineering, and how Herbert Boyer and Robert Swanson turned the science into a commercial product by developing recombinant insulin.

  scientificdiscovery.dev

Co-founder and chief executive of Sierra, chairman of the board of OpenAI, and formerly co-chief executive of Salesforce and chief technology officer of Facebook.

• Our readingkorrents.com

  Buyers default to buying from platforms until a new technology arrives, which swings them to best-of-breed because incumbents are bad at what is new.

  Their words

  When new technologies come out, this pendulum swings from best of platform towards best of breed. And the reason for that is incumbents typically aren't that great at these new technologies.

  youtube.com

Writes about the biotech industry, drug development and forecasting — “I write to learn, mostly about biotech.”

• Our readingkorrents.com

  A computational discovery platform does not make a biotech fast, because the thousand other steps of drug development are still the bottleneck.

  Their words

  Another challenge for Class II biotechs is that even if you have a nifty computational drug discovery platform, you are still often bottlenecked by the rest of the drug development process. It takes 1,000 (or more!) small steps to advance a drug through discovery, development, and past the regulators.

  A new breed of biotechatelfo.github.io